These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
267 related articles for article (PubMed ID: 38102107)
21. Correlation between the potency of hallucinogens in the mouse head-twitch response assay and their behavioral and subjective effects in other species. Halberstadt AL; Chatha M; Klein AK; Wallach J; Brandt SD Neuropharmacology; 2020 May; 167():107933. PubMed ID: 31917152 [TBL] [Abstract][Full Text] [Related]
22. Beyond the 5-HT Cameron LP; Benetatos J; Lewis V; Bonniwell EM; Jaster AM; Moliner R; Castrén E; McCorvy JD; Palner M; Aguilar-Valles A J Neurosci; 2023 Nov; 43(45):7472-7482. PubMed ID: 37940583 [TBL] [Abstract][Full Text] [Related]
23. Serotonergic Psychedelics: Experimental Approaches for Assessing Mechanisms of Action. Canal CE Handb Exp Pharmacol; 2018; 252():227-260. PubMed ID: 29532180 [TBL] [Abstract][Full Text] [Related]
24. Support for 5-HT2C receptor functional selectivity in vivo utilizing structurally diverse, selective 5-HT2C receptor ligands and the 2,5-dimethoxy-4-iodoamphetamine elicited head-twitch response model. Canal CE; Booth RG; Morgan D Neuropharmacology; 2013 Jul; 70():112-21. PubMed ID: 23353901 [TBL] [Abstract][Full Text] [Related]
26. Enlightening the "Spirit Molecule": Photomodulation of the 5-HT Gerwe H; He F; Pottie E; Stove C; Decker M Angew Chem Int Ed Engl; 2022 Jun; 61(26):e202203034. PubMed ID: 35349196 [TBL] [Abstract][Full Text] [Related]
27. Antidepressant-like effects of psychedelics in a chronic despair mouse model: is the 5-HT Sekssaoui M; Bockaert J; Marin P; Bécamel C Neuropsychopharmacology; 2024 Mar; 49(4):747-756. PubMed ID: 38212441 [TBL] [Abstract][Full Text] [Related]
29. Chemistry and Structure-Activity Relationships of Psychedelics. Nichols DE Curr Top Behav Neurosci; 2018; 36():1-43. PubMed ID: 28401524 [TBL] [Abstract][Full Text] [Related]
30. Serotonin, but not N-methyltryptamines, activates the serotonin 2A receptor via a ß-arrestin2/Src/Akt signaling complex in vivo. Schmid CL; Bohn LM J Neurosci; 2010 Oct; 30(40):13513-24. PubMed ID: 20926677 [TBL] [Abstract][Full Text] [Related]
31. Role of 5-HT2A, 5-HT2C, 5-HT1A and TAAR1 Receptors in the Head Twitch Response Induced by 5-Hydroxytryptophan and Psilocybin: Translational Implications. Shahar O; Botvinnik A; Esh-Zuntz N; Brownstien M; Wolf R; Lotan A; Wolf G; Lerer B; Lifschytz T Int J Mol Sci; 2022 Nov; 23(22):. PubMed ID: 36430623 [TBL] [Abstract][Full Text] [Related]
32. Alterations in 5-HT2A receptor signaling in male and female transgenic rats over-expressing either Gq or RGS-insensitive Gq protein. Shi J; Damjanoska KJ; Zemaitaitis B; Garcia F; Carrasco G; Sullivan NR; She Y; Young KH; Battaglia G; Van De kar LD; Howland DS; Muma NA Neuropharmacology; 2006 Sep; 51(3):524-35. PubMed ID: 16769091 [TBL] [Abstract][Full Text] [Related]
33. A G Protein-biased Designer G Protein-coupled Receptor Useful for Studying the Physiological Relevance of Gq/11-dependent Signaling Pathways. Hu J; Stern M; Gimenez LE; Wanka L; Zhu L; Rossi M; Meister J; Inoue A; Beck-Sickinger AG; Gurevich VV; Wess J J Biol Chem; 2016 Apr; 291(15):7809-20. PubMed ID: 26851281 [TBL] [Abstract][Full Text] [Related]
35. Agonism, Antagonism, and Inverse Agonism Bias at the Ghrelin Receptor Signaling. M'Kadmi C; Leyris JP; Onfroy L; Galés C; Saulière A; Gagne D; Damian M; Mary S; Maingot M; Denoyelle S; Verdié P; Fehrentz JA; Martinez J; Banères JL; Marie J J Biol Chem; 2015 Nov; 290(45):27021-27039. PubMed ID: 26363071 [TBL] [Abstract][Full Text] [Related]
36. Effects of a psychedelic 5-HT2A receptor agonist on anxiety-related behavior and fear processing in mice. Pędzich BD; Rubens S; Sekssaoui M; Pierre A; Van Schuerbeek A; Marin P; Bockaert J; Valjent E; Bécamel C; De Bundel D Neuropsychopharmacology; 2022 Jun; 47(7):1304-1314. PubMed ID: 35449450 [TBL] [Abstract][Full Text] [Related]
37. Psychedelics promote neuroplasticity through the activation of intracellular 5-HT2A receptors. Vargas MV; Dunlap LE; Dong C; Carter SJ; Tombari RJ; Jami SA; Cameron LP; Patel SD; Hennessey JJ; Saeger HN; McCorvy JD; Gray JA; Tian L; Olson DE Science; 2023 Feb; 379(6633):700-706. PubMed ID: 36795823 [TBL] [Abstract][Full Text] [Related]
38. A non-hallucinogenic LSD analog with therapeutic potential for mood disorders. Lewis V; Bonniwell EM; Lanham JK; Ghaffari A; Sheshbaradaran H; Cao AB; Calkins MM; Bautista-Carro MA; Arsenault E; Telfer A; Taghavi-Abkuh FF; Malcolm NJ; El Sayegh F; Abizaid A; Schmid Y; Morton K; Halberstadt AL; Aguilar-Valles A; McCorvy JD Cell Rep; 2023 Mar; 42(3):112203. PubMed ID: 36884348 [TBL] [Abstract][Full Text] [Related]